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THE ROLE OF N-SULFATION IN THE PROMOTION PHASE OF 
CARCINOGENESIS BY N-HYDROXY-2-ACETYLAMINOFLUORENE
IN MALE RAT LIVER.
E.D.Kroese, M.L.M van de Poll, G.J.Mulder and J .H .N .Meerman
The liver is one of the organs in the male rat that is 
highly susceptible to the carcinogenic action of N-hydroxy- 
2-acetylaminofluorene (N-OH-AAF). A major route for the 
formation of reactive intermediates and macromolecular 
adducts from this carcinogen is N-sulfation through sulfo- 
transferases. The role of this N-sulfation in the promotion 
phase of carcinogenesis by N-OH-AAF was the objective of 
this study. We used an initiation-promotion (selection) 
model for tumor-induction as originally developed by 
Roberts and colleagues (1). This model consists of 
treatment with diethylnitrosamine (single dose; initiation) 
followed by N-OH-AAF (several doses) coupled with partial 
hepatectomy (promotion/selection). The focal liver cell 
populations (foci), which are the first aberrant cells 
that appear with this treatment are considered to be 
preneoplastic lesions and c^n be detected by )—glutamyl- 
transpeptidase staining (GGT ). The effects of inhibition 
of sulfotransferase activity towards N-OH-AAF with 
pentachlorophenol (PCP (2))+ during N-OH-AAF treatment on 
the number and volume of GGT foci was investigated.
PCP treatment during promotion with N-OH-AAF reduced the 
volume occupied by GGT -cells lj>y 65% , without significant­
ly affecting the number of GGT foci found per cubical cm. 
It is therefore concluded, that promotion (selection) by 
N-OH-AAF of initiated cells depends for a large part on the 
sulfotransferase pathway.
1. E.Roberts et al, AACR 43(3) (1985) 135.
2. J.H.N.Meerman and G.J.Mulder, Life Sciences 28 (1981) 
2361.
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DNA ALKYLATION AND CROSSLINKING BY REDUCTIVELY ACTIVATED
2,5-8IS(1-AZIRIDINYL)-l,4-B ENZOQUI NON E ANTITUMOUR COM­
POUNDS
K.J. Lusthof, N.J. de M o l , L.H.M. Janssen
Bisaziridinyl benzoquinones are potential antitumour com­
pounds, that are assumed to be bioreductively activated. 
We investigated a series of bisaziridinyl-benzoquinones 
synthesized by the Organic Chemistry Department of the 
Technical University of Twente. Previously, these com­
pounds were shown to kill DNA-repair deficient E.coli and 
to inactivate bacteriophage-M13 DNA.
Alkylation of DNA by the unsubstituted title compound 
(TW13) was studied by means of UV-absorbance after removal 
of unbound quinone. Crosslinking of DNA was measured with 
an ethidium bromide fluorescence assay.
DNA alkylation as well as crosslinking appeared to in­
crease strongly with decreasing pH, indicating the role of 
protonation of the aziridine rings in the alkylation pro­
cess. The increase of alkylation and crosslink formation 
occurs at higher pH when the quinones are reduced.
This is expected because reduction facilitates protonation 
of the aziridine groups. At pH 7, DNA alkylation increased 
linearly with the amount of reduction. The similarity in 
pH dependence of M13-DNA inactivation and alkylation indi­
cates that DNA inactivation is mainly caused by alkyla­
tion. The relationship between the extent of crosslinking 
and inactivation of M13-DNA was only weak.
Méthylation of the aziridine group was shown to decrease 
strongly M13 inactivation and DNA crosslinking.
Generally, our results are in agreement with the concept 
that reductive activation is the major mechanism of action 
by producing modifications at the DNA level.
Dept. Pharmaceutical Chemistry/Chemical Pharmacy, Faculty 
of Pharmacy, University of Utrecht, Catharijnesingel 60, 
3511 GH Utrecht, The Netherlands.
CADMIUM INHIBITION OF CALCIUM TRANSPORT IN FISH GILLS 
R.A.C. Lock, P.M. Verbost, G. Plik and S.E. Wendelaar Bonra
Freshwater fish take up most of the Ca necessary for growth 
and Ca-homeostasis from the water via their trills.A  , # u
Ca^ -inflow is a transcellular process involving an ATP- 
dependent Ca^-transport mediated by a "high-affinity" Ca‘1 + 
-ATPase at the basolateral membrane system (l).
Exposure of rainbow trout (Salmo gaivdnevi) to cadmium in 
the water rapidly leads to hypocalcemia. Experimental evi­
dence is supplied that such disturbance is the result of 
decreased branchial Ca^+-transport due to inhibited Ca^+- 
ATPase activity.
We have tested the effects of Cd1- in the water on net 
branchial Ca"+-flow {inflow minus ef f low) in perfused trout 
gills (2) and on the Ca‘+-ATPase activity in the isolated 
gill plasma membranes. Characteristics of the Ca^+-ATPase 
activity are: an affinity for Ca-+ in the uM range, ATP 
preference, and calmodulin dependency. The desired Cac+- 
concentration (10“C’ M) and the free Cd-’ + -concentrations 
( 10“9 -i0-^’ M) in the Ca,+-buffer were calculated on the 
basis of established (Ca)(3) and newly determined (Cd) 
binding constants of the ligands.
Exposure of trout to^lO-1 M Cd^+ reduced the CaJ+ - inf low 
by 79%, while the CaJ+- e f f l o v remained unaffected. Cd^+ 
also proved to specifically inhibit [in vi t ro) the "high- 
affinity" Ca^-ATPase activity (IC50: M Cd^+ ).
This inhibition is apparently not caused by Cdt-’+ binding 
to calmodulin but rather by a direct competition with Ca1- + 
for the Ca-^-transport site of the Ca^+-ATPase.
1. G. Flik, S.E. Wendelaar Bonga and J.C. Fenwick, Comp. 
Biochem. Physiol., 79B ( 198M 9
2. P.M. Verbost, G. Flik, R.A.C. Lock and S.E. Wendelaar 
Bonga, Am. J. Physiol., 253 (1987) 216
3. M.P.E. van Heeswijk, J.A.M. Geertsen and C.H. van Os,
J. Membrane Biol., 79 ( 198M 19
Dept, of Zoology, University of Nijmegen, Toernooiveld,
6525 ED Nijmegen, The Netherlands
CYTOTOXICITY AND BIOTRANSFORMATION STUDIES WITH 
BROMOBENZENE IN RAT HEPATOCYTE CULTURES
W.C. Mennes, R. den Hartogh and B.J. Blaauboer
Bromobenzene (BrB) is toxic to hepatocytes in vivo as well 
as in vitro. This toxicity is related to biotransformation 
and GSH depletion. BrB hepatotoxicity is elicited by 
metabolites that are generated by phenobarbital (PB) indu­
cible forms of cytochrome P-450, i.e. isoenzymes belonging 
to family II. In hepatocyte primary cultures a loss in 
cytochrome P-450 level is observed. In rat hepatocytes this 
loss is greater than in hepatocytes derived from other 
mammalian species (1). Little is known about the behaviour 
of the different cytochrome P—450 isoenzymes and their 
residual activities in primary hepatocyte cultures.
In order to validate the use of hepatocyte cultures as ijn 
vitro model system for studying biotransformation, we 
investigated BrB cytotoxicity and biotransformation in rat 
hepatocytes immediately after cell isolation and after 24 h 
in primary culture. Toxicity (at conc up to 2 mM) was only 
observed in the freshly isolated cells. In these cells the 
levels of GSH were considerably lower than in cells after 
24 h in culture. A BrB-dependent decrease in GSH was found 
in cells after exposure for 24 h. GSH/GSSG ratios changed 
from about 3 in control cells to about l.S in cells exposed 
to 2 mM BrB. BrB was metabolised to 2-, 3-, and 
4-bromophenol, which were conjugated with glucuronic acid 
and sulphate. No changes in the ratio of 4-bromo- 
phenol/2-bromophenol were observed.
These results indicate that cytochrome P-450 isoenzymes 
involved in BrB metabolism belonging to family I and II are 
approximately equally stable in rat hepatocyte primary 
culture. Similar studies with liver cells derived from 
other mammalian species are in progress.
I. W.C. Mennes, B.J. Blaauboer and C.W.M. van Holsteijn, 
Proc. Symp. on Liver Cells and Drugs, Rennes (1987), 
in press.
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